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Tartrate-resistant acid phosphataseTmem173 was identiﬁed as a growth inhibitor associated with major histocompatibility complex
(MHC) class II and a potential stimulator for IFN-b, an innate immune inducer and a negative feed-
back controller for RANKL-induced osteoclast differentiation of monocytic macrophage cells. In this
study, we conﬁrmed that transmembrane protein 173 (Tmem173) overexpression inhibited the
expression of osteoclast-speciﬁc genes, tartrate-resistant acid phosphatase (TRAP), cathepsin K,
and matrix metalloproteinase-9 (MMP-9), as well as bone resorption pit formation in RANKL-treated
RAW 264.7 cells. Activation of osteoclast-speciﬁc transcription factors, c-Fos and nuclear factor of
activated T cells cytoplasmic-1 (NFATc1), and RANKL-induced activation of ERK were also down-
regulated by Tmem173 overexpression. Collectively, these results suggest that Tmem173 plays a
regulatory role in RANKL–RANK-mediated signaling in osteoclastogenesis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Homeostasis of bone mass is maintained via bone remodeling
by osteoblasts and osteoclasts, which are responsible for bone for-
mation and resorption, respectively. The balance of osteoblasts and
osteoclasts is important for maintaining bone density and exces-
sive osteoclast activity can lead to various bone diseases such as
osteoporosis, periodontal disease, and rheumatoid arthritis.
Therefore, investigation of the key factors involved in osteoclast
differentiation and function is crucial for the development oftherapeutic agents and control strategies for the diseases involved
in bone remodeling [1].
Osteoclasts are multinucleated giant cells, which originate from
the fusion of monocyte/macrophage lineage cells. Osteoclast differ-
entiation requires two essential factors, macrophage colony-s-
timulating factor (M-CSF) and RANKL, both of which are
expressed on osteoblast/stromal cells [1,2]. Speciﬁcally, RANKL, a
member of the tumor necrosis factor (TNF) cytokine family, is a
key positive regulator of osteoclast differentiation. RANKL induces
the activation of mitogen-activated protein (MAP) kinases and var-
ious transcription factors including nuclear factor kappa B (NF-jB),
AP1, PU.1, c-Fos, and NFATc1 during osteoclastogenesis [1,2]. c-Fos
and NFATc1 act as major transcription factors and induce expres-
sion of osteoclast-speciﬁc genes such as tartrate-resistant acid
phosphatase (TRAP), cathepsin K, and MMP-9 during RANKL-
stimulated osteoclastogenesis. Of these genes, TRAP plays an
important role in osteoclastic bone resorption and can induce
dephosphorylation and resorption of bone matrices [3,4].
Cathepsin K is a cysteine protease secreted by osteoclasts and is
in part responsible for the degradation of collagen during bone
resorption [5]. MMP-9, also known as gelatinase B and type IV col-
lagenase, is highly expressed in osteoclasts and plays an important
role in the degradation of extracellular matrix of bone [6].
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manner, such as through RANKL clearance and ubiquitin-mediated
down-regulation of NFATc1 [7,8]. Osteoprotegerin (OPG), well-
known as an osteoclastogenesis inhibitory factor (OCIF), interrupts
the RANKL–RANK interaction between osteoblast/stromal cells and
osteoclast precursors. This blockage can result in the inhibition of
differentiation of osteoclast precursors into mature osteoclasts
[9]. In addition, IFN-b, a member of a cytokine family of type I
interferons, has also been identiﬁed as a typical negative regulator
of RANKL-induced osteoclast differentiation. RANKL induces IFN-b
expression via c-Fos and in turn, IFN-b inhibits osteoclast differen-
tiation by preventing RANKL-induced c-Fos expression [10,11].
Establishment of this negative feedback regulation of RANKL-c-
Fos-IFN-b is a key factor in the development of new therapeutic
targets for treating bone loss associated with various diseases [11].
Tmem173, also known as STING,MPYS andMITA, is a four-trans-
membrane protein that was originally identiﬁed as a growth inhibi-
tor that mediates anti-MHC class II antibody-induced death in B
lymphoma cells [12]. Later, it was found that Tmem173 is also asso-
ciated withMHC class II andmediates the transduction of apoptotic
signals. In addition, Tmem173 acts as a potential IFN-b stimulator in
monocyte/macrophage cells, and is essential for innate immune
responses to RNA and DNA viruses [13,14]. With respect to its IFN-
b-inducing abilities and growth inhibition of MHC class II-express-
ing monocytic cells including macrophages and osteoclast pro-
genitor cells, we postulated that Tmem173 could be applied as an
inhibitory regulator in osteoclastogenesis. In this study,we explored
the regulatory role of Tmem173 on osteoclast differentiation using
the murine monocytic macrophage/osteoclast progenitor cell line
RAW264.7, which iswidely used for the study of osteoclastogenesis
in vitro [15,16]. We investigated the effect of Tmem173 on RANKL-
induced osteoclastogenesis by assessing osteoclast-associated gene
expression and protein activation in Tmem173-overexpressed
RAW264.7 cells. We veriﬁed that overexpression of Tmem173
down-regulated osteoclast differentiation by inhibiting RANKL-
induced signal transduction involved in osteoclastogenesis.
2. Materials and methods
2.1. Reagents
All chemicals were purchased from Sigma Chemical Co. unless
otherwise speciﬁed. Dulbecco’s Modiﬁed Eagle’s Media (DMEM)
and fetal bovine serum (FBS) were obtained fromHyClone Laborato-
ries, Inc. Mouse soluble RANKL was obtained from PeproTech, Inc.
TRIzol RNA extraction reagent was obtained from Molecular
Research Center, Inc. Lipofectamine 2000 transfection reagent
was obtained from Invitrogen™ Life Technologies. The Reverse
Transcription System was obtained from Promega. Mouse mono-
clonal antibody against phosphorylated ERK (p-ERK) (ERK 1
phosphorylated at Tyr 204 and phosphorylated ERK 2) and rabbit
polyclonal antibody against ERK 2 were obtained from Santa Cruz
Biotechnology, Inc. Secondary antibodies conjugated with horserad-
ish peroxidase (HRP)were obtained fromGEHealthcare Life Sciences.
2.2. Cell culture and generation of transfected cells
RAW264.7 cells were cultured in DMEM containing 10% FBS at
37 C in a 5% CO2 incubator. In order to transfect cells with the
Tmem173 gene, RAW264.7 cells were plated on 12-well culture
plates at a density of 5  105 cells/well, 1 day prior to transfection.
Either control vector or pcDNA-Tmem173 were mixed with
Lipofectamine 2000 and transfected into the cells according to
the manufacturer’s protocol. The pcDNA-Tmem173- or control
vector-transfected RAW264.7 cells were cultured in DMEM con-
taining 10% FBS and neomycin.In order to knock-down Tmem173 in RAW264.7 cells, GIPZ
Tmem173 shRNA Transduction Starter Kit (GE Healthcare Life
Sciences) was used. Brieﬂy, RAW264.7 cells were plated on 12-well
plates at a density of 5  105 cells/well 1 day prior to transfection.
Non-silencing vector control or pGIPZ-Tmem173 shRNA was
mixed with transfection reagent and transfected into the cells
according to the manufacturer’s protocol. The pGIPZ-Tmem173
shRNA- or non-silencing vector control-transfected RAW264.7
cells were cultured in DMEM containing 10% FBS and puromycin.
2.3. TRAP activity assay
Cells (2  105 cells/ml) were distributed into 6-well plates in
the presence of 50 ng/ml of RANKL and incubated for 4 days.
Culture medium was removed and the cells were gently washed
twice with PBS. The cells were then lysed with 500 ll of 50 mM
sodium acetate buffer (pH 7.4) containing 0.1% Triton X-100.
TRAP activity in the cell lysates was determined using TRAP solu-
tion (125 mM sodium acetate buffer, pH 5.2, containing 1 mM
sodium tartrate, and 100 mM p-nitrophenyl phosphate) at 37 C
for 30 min. The reaction was stopped by adding 0.1 N NaOH and
the absorbance was measured at 405 nm using a microplate reader
(Packard Instrument Co.).
2.4. Pit formation assay
Bone resorption function was analyzed using the bone resorp-
tion assay plate (Cosmo Bio Co., Ltd.). Brieﬂy, cells (2  105 cells/
ml) were plated into 24-well plates and treated with RANKL
(100 ng/ml) for 6 days. Cultured cells were then removed using
5% sodium hypochlorite treatment for 5 min. Pit areas on the wells
were observed under a light microscope and analyzed by Image J
software.
2.5. RNA isolation and RT-PCR
Cells (2  105 cells/ml) were plated into 6-well plates, exposed
to 50 ng/ml RANKL, and incubated for 4 days. Total RNA was
extracted from cells using TRIZOL reagent and quantiﬁed by spec-
trophotometry. Complementary DNA was synthesized from total
RNA using the Reverse Transcription System and ampliﬁed through
PCR. The PCR products were separated by electrophoresis in a 1.2%
agarose gel.
2.6. Western blot analysis
Vector control-transfected and Tmem173-overexpressed
RAW264.7 cells were cultured in 60-mm plate for 30 min with
RANKL (50 ng/ml). Cultured cells were then extracted using RIPA
buffer containing inhibitors for protease and phosphatase
(Thermo Fisher Scientiﬁc Inc.). The cell lysates were separated on
a 12% SDS–PAGE gel and blotted to a PVDF membrane. The blot
was blocked for 1 h at room temperature with 5% non-fat dry milk
and incubated with target protein-speciﬁc antibodies. The blot was
rinsed and then incubated with secondary antibodies. Proteins
were then visualized on X-ray ﬁlm by adding substrates for
enhanced chemiluminescence (Pierce Protein Biology, Thermo
Fisher Scientiﬁc).
2.7. Statistical analyses
Statistical analyses were performed using SigmaPlot™ (Systat
Software). Results are presented as the mean ± standard error.
Unpaired Student’s t-test was used to compare groups, and P-val-
ues less than 0.05 were considered statistically signiﬁcant.
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3.1. Overexpression of Tmem173 inhibits TRAP activity and pit
formation in RANKL-treated RAW264.7 cells
In order to examine the effect of Tmem173 on osteoclast differ-
entiation, we initially established control vector- or Tmem173-
transfected RAW264.7 cells and the expression of transfected
Tmem173 was conﬁrmed (data not shown). We then measured
TRAP activity in the cells in the presence of RANKL since TRAP is
a well-known histochemical marker enzyme in osteoclasts, is
abundantly expressed by osteoclasts, and plays an important roleFig. 1. Overexpression of Tmem173 down-regulates RANKL-induced osteoclast
differentiation from RAW264.7 cells. (A) Overexpression of Tmem173 inhibited the
RANKL-induced activation of TRAP activity. Control vector- and Tmem173-trans-
fected RAW264.7 cells were treated with RANKL, and TRAP activity was measured
as described in Section 2. (B) Overexpression of Tmem173 inhibited the RANKL-
induced pit formation in RAW264.7 cells. Control vector- and Tmem173-transfect-
ed RAW264.7 cells were cultured with RANKL on bone resorption assay plates and
pit formation was measured as described in Section 2. ⁄⁄⁄P < 0.001 indicate
signiﬁcant differences in each indicated treatment. A representative result from
three independent experiments is shown.in osteoclastic bone resorption [2,4]. TRAP activity in RANKL-treat-
ed RAW264.7 cells was signiﬁcantly down-regulated by 60.4% in
Tmem173-transfected cells compared to control vector-transfect-
ed cells (Fig. 1A). Next, we examined the effect of Tmem173 over-
expression on osteoclastogenesis by measuring bone resorption
activity through a pit formation assay using calcium phosphate-
coated culture plate because osteoclasts are able to generate
resorption pits on bone (Fig. 1B). A number of resorption pit areas
were examined in the RANKL-treated RAW264.7 cells that had
been transfected with control vector. Interestingly, the resorption
pit areas decreased signiﬁcantly in the wells containing
Tmem173-overexpressed and RANKL-treated RAW264.7 cells
compared to the wells containing control vector-transfected cells.
We conﬁrmed the inhibitory activity of Tmem173 on TRAP and
bone resorption in RANKL-stimulated RAW264.7 cells using cells
in which Tmem173 expression had been knocked down (Fig. S1).
Initially we tested two different shRNA constructs and found that
sh1RNA more efﬁciently inhibited Tmem173 gene expression
(Fig. S1A). When we applied sh1RNA for Tmem173 knock-down,
up-regulation of TRAP activity (Fig. S1B) and pit formation
(Fig. S1C) was detected in RANKL-treated Tmem173 knock-down
cells. These results suggest that Tmem73 overexpression inhibits
TRAP activity and pit formation in RANKL-stimulated osteoclast
precursor cells.
3.2. Overexpression of Tmem173 inhibits expression of osteoclast-
speciﬁc genes during RANKL-induced osteoclastogenesis
RANKL has been previously characterized as an inducer of
expression for several osteoclast-speciﬁc genes such as TRAP,
cathepsin K, and MMP-9 during osteoclastogenesis [1,2]. Based
on the observed inhibitory effect of Tmem173 overexpression on
TRAP activity and pit formation in RANKL-treated RAW264.7 cells,
we next analyzed the inﬂuence of Tmem173 on osteoclast-speciﬁc
gene expression (Fig. 2). RANKL-induced expression of TRAP,
cathepsin K, and MMP-9 genes was down-regulated in
Tmem173-overexpressed RAW264.7 cells compared to expression
in control vector-transfected cells (Fig. 2A). We conﬁrmed the
inhibitory activity of Tmem173 on RANKL-induced expression of
these genes using cells in which Tmem173 expression had been
knocked down. When we applied sh1RNA for Tmem173 knock-
down, up-regulation of TRAP, cathepsin K, and MMP-9 gene
expression was detected 4 days after RANKL treatment (Fig. 2B).
In particular, TRAP expression was prominently detected on the
second day of transfection in Tmem173 knock-down cells com-
pared to that in non-silencing control vector-transfected cells, in
which TRAP expression was hardly detected (data not shown).
Collectively, it was conﬁrmed that Tmem173 is able to negatively
modulate the expression of genes involved in RANKL-induced
osteoclastogenesis.
3.3. Tmem173 overexpression inhibits RANKL-induced expression of
osteoclast-speciﬁc transcription factors and ERK MAP kinase
activation
c-Fos and NFATc1 are key transcription factors regulating osteo-
clast differentiation and c-Fos is an up-stream regulator that
induces expression of NFATc1. NFATc1 is one of the main regula-
tors of osteoclast differentiation and induces the expression of var-
ious osteoclast-speciﬁc genes [1,2]. We examined the regulation of
transcription factor activation in response to Tmem173 overex-
pression (Fig. 3A). Expression levels of c-Fos and NFATc1, which
were enhanced by RANKL treatment in control vector-transfected
RAW264.7 cells, were prominently down-regulated in Tmem173-
overexpressed cells. Because RANKL–RANK interaction leads to
the activation of signaling pathways mediated by ERK MAP kinase
Fig. 2. Tmem173 overexpression suppresses the expression of osteoclast-speciﬁc
genes in RANKL-treated RAW264.7 cells. (A) Overexpression of Tmem173 down-
regulated the expression of osteoclast-speciﬁc genes. Control vector- and
Tmem173-transfected RAW264.7 cells were cultured with RANKL and the expres-
sion of indicated genes was analyzed from total RNA isolated from cultured cells
using RT-PCR as described in Section 2. (B) Expression of osteoclast-speciﬁc genes
was up-regulated via knock-down of Tmem173 in RANKL-stimulated RAW264.7
cells. Non-silencing control (Control-RAW264.7) and Tmem173 knock-down
(Tmem173 sh1RNA-RAW264.7) cells were cultured with RANKL and the expression
of indicated genes was analyzed from total RNA isolated from the cultured cells
using RT-PCR as described in Section 2.
Fig. 3. Overexpression of Tmem173 down-regulated the expression of osteoclast-
speciﬁc factors in RANKL-induced RAW264.7 cells. (A) Tmem173 overexpression
down-regulated the osteoclast-speciﬁc transcription factors. Control vector- and
Tmem173-transfected RAW264.7 cells were cultured with RANKL and the expres-
sion of indicated genes was analyzed from total RNA isolated from the cultured cells
using RT-PCR as described in Section 2. (B) Overexpression of Tmem173 suppressed
RANKL-induced activation of ERK MAP kinase. Control vector- and Tmem173-
transfected RAW264.7 cells were cultured with RANKL and the activation of ERK
was analyzed from the total protein isolated from the cells through Western blot by
using antibodies against phosphorylated ERKs. (C) Overexpression and knock-down
of Tmem173 enhanced and inhibited expression of IFN-b, respectively, in RANKL-
stimulated RAW264.7 cells. Cells treated as indicated were cultured with RANKL
and the expression of IFN-bwas analyzed from total RNA isolated from the cultured
cells using RT-PCR, as described in Section 2.
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[17], we monitored the effect of Tmem173 overexpression on ERK
MAP kinase activation (Fig. 3B). Western blot analysis using ERK-
and p-ERK-speciﬁc antibodies showed that RAW264.7 cells treated
with RANKL for 30 min exhibited an increased level of p-ERK.
Importantly, this RANKL-mediated increase in the level of p-ERK
was down-regulated in Tmem173-overexpressed RAW264.7 cells.
We next analyzed the expression of IFN-b, a negative regulator of
c-Fos in RANKL-induced osteoclast differentiation (Fig. 3C). As
expected, IFN-b expression in RANKL-treated RAW264.7 cells was
enhanced by Tmem173 overexpression compared to that in control
vector-transfected cells (Fig. 3C, upper panel). On the contrary,
IFN-b expression was down-regulated in Tmem173 knock-down
cells compared to that in non-silencing control vector-transfected
cells (Fig. 3C, lower panel). These results indicate that overexpres-
sion of Tmem173 activates IFN-b gene expression and inhibits
RANKL-induced activation of c-Fos and NFATc1 through modula-
tion of ERK activation during osteoclastogenesis.
3.4. OPG induces the expression of Tmem173 in RANKL-stimulated
RAW24.7 cells
Since the RANK/RANKL/OPG pathway was discovered to be
involved in osteoclastogenesis, studies on the regulation of osteo-
clastogenesis have been concentrated on the analysis of biological-
ly-related TNF receptor/TNF-related proteins like OPG, RANK, and
RANKL [9]. Among these proteins, OPG represents a negative
regulator of osteoclast differentiation. When we analyzed the inﬂu-
ence of OPG treatment on the expression of Tmem173 inRAW264.7 cells, Tmem173 expression increased in a dose-depen-
dent manner in response to OPG treatment (Fig. 4). Conversely,
TRAP expression dose-dependently decreased in response to OPG
treatment. These results suggest that OPG induces the expression
of Teme173 in osteoclast precursor cells and that Tmem173 is
closely related to the OPG–RANKL–RANK network in
osteoclastogenesis.
4. Discussion
Osteoclast differentiation is a key regulatory point for bone dis-
ease therapy and is known to be regulated by several factors
Fig. 4. OPG dose-dependently induced the expression of Tmem173 in RANKL-
stimulated RAW264.7 cells. RAW264.7 cells were cultured with RANKL together
with different concentrations of OPG. Total RNA was prepared from cultured cells
and the expression of indicated genes was analyzed using RT-PCR as described in
Section 2.
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interleukin and eicosanoid production environment is also
involved in the regulation of bone turnover, and abnormal produc-
tion of these mediators is responsible for the development of var-
ious bone diseases [18]. Speciﬁcally, IFN-b exhibited a strong
inhibitory effect on in vitro osteoclastogenesis from primary osteo-
clast precursors treated with RANKL and M-CSF [10,11]. IFN-b pro-
duction is induced by RANK–RANKL interaction via the induction
of c-Fos. IFN-b, in turn, inhibits c-Fos production in a negative feed-
back manner through the JAK/STAT pathway, which induces the
IFN-inducible genes including protein kinase R resulting in the
suppression of c-Fos protein expression [11]. Therefore, these
endogenous factors, including IFN-b, are major therapeutic targets
for diseases linked to bone loss.
Tmem173 was ﬁrst identiﬁed as a growth inhibitor associated
with MHC class II that mediates cell death signals in B lymphoma
cells. In addition, it has been reported that Tmem173 is an IFN-b
stimulator in monocyte/macrophage cells, and overexpression in
293T cells activated the IFN-b promoter [19]. Due to these reports,
we postulated a role of Tmem173 as a potential inhibitory regula-
tor of osteoclastogenesis based on its ability to induce IFN-b pro-
duction and inhibit the growth of MHC class II-expressing
monocytic cells including macrophages and osteoclast progenitor
cells. In accordance with this hypothesis, we demonstrated the
inhibitory effect of Tmem173 overexpression on RANKL-induced
osteoclast differentiation by quantifying TRAP activity, which is
prominent in osteoclasts. We observed that both TRAP activity
and bone resorption were signiﬁcantly reduced in Tmem173-over-
expressed RAW264.7 cells (Fig. 1). Markers of osteoclast differen-
tiation and morphological changes, including TRAP, cathepsin K,
and MMP-9, all showed a similar pattern of down-regulation in
Tmem173-overexpressed RAW264.7 cells (Fig. 2). Osteoclast dif-
ferentiation was also up-regulated more efﬁciently in RAW264.7
cells in which Tmem173 had been knocked down compared to
non-silencing control vector-transfected cells (Figs. 2B and S1).
Since the discovery of the RANKL/RANK system in the late
1990s, many studies have been focused on elucidating the RANK-
initiated signaling pathway involved in differentiation, function,
and survival of osteoclasts. As a result of these studies, it has been
demonstrated that RANK activates signaling pathways in osteo-
clasts mediated by NFATc1, NF-jB, Akt/protein kinase B (PKB),
Jun N-terminal kinase (JNK), ERK, and p38 [20]. ERK MAP kinase
is a key player in the downstream signaling complexes of TRAF6
in RANKL-induced osteoclastogenesis and induces the expression
of essential transcription factors including c-Fos during osteoclas-
togenesis [17]. Importantly, it has been shown that modulation
of ERK activity by an ERK/MEK inhibitor resulted in down-regula-
tion of TRAP activity [21]. We analyzed the Tmem173 regulation
of c-Fos and NFATc1, two osteoclast-speciﬁc transcription factors,
and found that the transcription factors were down-regulated by
overexpression of Tmem173 in RAW264.7 cells (Fig. 3A). In addi-
tion, we observed that ERK activation was reduced by overexpres-
sion of Tmem173 and these results showed that the induction ofTmem173 expression inhibited osteoclast differentiation by sup-
pressing the RANKL-induced expression of c-Fos, NFATc1, and
ERK activation (Fig. 3A and B). Given that IFN-b inhibits RANKL-in-
duced osteoclast differentiation through suppression of c-Fos
expression [11], it is conceivable that Tmem173 suppresses
expression of c-Fos via enhancement of IFN-b expression during
RANKL-induced osteoclastogenesis. OPG is a decoy receptor for
RANKL and has previously been shown to be a secreted TNF recep-
tor-related protein capable of blocking osteoclast formation in vitro
and bone resorption in vivo [22,23]. Interestingly, we also observed
up-regulation of Tmem173 expression by OPG, a negative regula-
tor of osteoclast differentiation, in RAW264.7 cells (Fig. 4).
Collectively, these observations suggest that Tmem173 possibly
communicates with the RANKL–RANK signaling/OPG-stimulated
signaling network in osteoclastogenesis.
Various anti-bone resorptive agents for treating osteoporosis
include estrogen, selective estrogen receptor modulators
(SERMs), and bisphosphonates have been developed [24].
However, estrogen therapy has been associated with several
adverse effects such as vascular events and breast carcinoma
[25]. SERMS, which exert a similar effect to estrogen, can also
increase venous thromboembolic events and hot ﬂushes [26].
Bisphosphonates, the most commonly prescribed drug for the
treatment of osteoporosis, exhibit side effects such as osteonecro-
sis of the jaw, atrial ﬁbrillation, and atypical fractures [27].
Therefore, the development of effective therapies to manage bone
loss remains controversial, and no deﬁnite, standard therapy exists
to treat bone loss. Consequently, current studies are concentrated
on different mediators and regulatory factors involved in osteo-
clastogenesis to ﬁnd an effective healing process for bone defects.
In this study, we conﬁrmed that Tmem173 played a regulatory role
in RANKL-induced osteoclastogenesis and found an additional sup-
pressive regulator of the RANKL signaling pathway involved in
osteoclastogenesis. More importantly, this new ﬁnding supports
the hypothesis that Tmem173 could be a novel therapeutic target
for the treatment of osteoclast-mediated bone diseases. Further
studies will be required, however, to reveal the molecular basis
of the Tmem173-associated regulatory pathway.Authors contribution
JK and YSJ conceived and supervised the study; CHC, ISP, JP, and
KYY performed experiments; HJ analyzed data and provided com-
ments for bone study.
Acknowledgements
This study was supported by Basic Science Research Program
through the National Research Foundation of Korea (NRF)
funded by Korean Ministry of Science, ICT & Future Planning
(2011-0022168) and R&D Program funded by the Provincial
Government of Jeollabuk-do. Mr. J. Park was supported by the
BK21 Plus program in the Department of Bioactive Material
Sciences.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2015.02.
018.
References
[1] Walsh, M.C., Kim, N., Kadono, Y., Rho, J., Lee, S.Y., Lorenzo, J. and Choi, Y. (2006)
Osteoimmunology: interplay between the immune system and bone
metabolism. Annu. Rev. Immunol. 24, 33–63.
C.-H. Choe et al. / FEBS Letters 589 (2015) 836–841 841[2] Takayanagi, H. (2007) Osteoimmunology: shared mechanisms and crosstalk
between the immune and bone systems. Nat. Rev. Immunol. 7, 292–304.
[3] Ek-Rylander, B., Flores, M., Wendel, M., Heinegård, D. and Andersson, G. (1994)
Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic
tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion
in vitro. J. Biol. Chem. 269, 14853–14856.
[4] Harada, K., Itoh, H., Kawazoe, Y., Miyazaki, S., Doi, K., Kubo, T., Akagawa, Y. and
Shiba, T. (2013) Polyphosphate-mediated inhibition of tartrate-resistant acid
phosphatase and suppression of bone resorption of osteoclasts. PLoS ONE 8,
e78612.
[5] Matsumoto, M., Kogawa, M., Wada, S., Takayanagi, H., Tsujimoto, M.,
Katayama, S., Hisatake, K. and Nogi, Y. (2004) Essential role of p38 mitogen-
activated protein kinase in cathepsin K gene expression during
osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem.
279, 45969–45979.
[6] Sundaram, K., Nishimura, R., Senn, J., Youssef, R.F., London, S.D. and Reddy, S.V.
(2007) RANK ligand signaling modulates the matrix metalloproteinase-9 gene
expression during osteoclast differentiation. Exp. Cell Res. 313, 168–178.
[7] Gibiansky, L., Sutjandra, L., Doshi, S., Zheng, J., Sohn, W., Peterson, M.C., Jang,
G.R., Chow, A.T. and Pérez-Ruixo, J.J. (2012) Population pharmacokinetic
analysis of denosumab in patients with bone metastases from solid tumours.
Clin. Pharmacokinet. 51, 247–260.
[8] Kim, J.H., Kim, K., Jin, H.M., Song, I., Youn, B.U., Lee, S.H., Choi, Y. and Kim, N.
(2010) Negative feedback control of osteoclast formation through ubiquitin-
mediated down-regulation of NFATc1. J. Biol. Chem. 285, 5224–5231.
[9] Khosla, S. (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology
142, 5050–5055.
[10] Abraham, A.K., Ramanathan, M., Weinstock-Guttman, B. and Mager, D.E.
(2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem.
Pharmacol. 77, 1757–1762.
[11] Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H., Suzuki, T., Sato, K., Yokochi, T.,
Oda, H., Nakamura, K., Ida, N., Wagner, E.F. and Taniguchi, T. (2002) RANKL
maintains bone homeostasis through c-Fos-dependent induction of
interferon-beta. Nature 416, 744–749.
[12] Jin, L., Waterman, P.M., Jonscher, K.R., Short, C.M., Reisdorph, N.A. and
Cambier, J.C. (2008) MPYS, a novel membrane tetraspanner, is associated
with major histocompatibility complex class II and mediates transduction of
apoptotic signals. Mol. Cell Biol. 28, 5014–5026.
[13] Nakhaei, P., Hiscott, J. and Lin, R. (2010) STING-ing the antiviral pathway. J.
Mol. Cell Biol. 2, 110–112.
[14] Zhong, B., Yang, Y., Li, S., Wang, Y.Y., Li, Y., Diao, F., Lei, C., He, X., Zhang, L., Tien,
P. and Shu, H.B. (2008) The adaptor protein MITA links virus-sensing receptors
to IRF3 transcription factor activation. Immunity 29, 538–550.[15] Rahman, M.M., Bhattacharya, A. and Fernandes, G. (2008) Docosahexaenoic
acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells
than eicosapentaenoic acid. J. Cell. Physiol. 214, 201–209.
[16] Rahman, M.M., Bhattacharya, A. and Fernandes, G. (2006) Conjugated linoleic
acid inhibits osteoclast differentiation of RAW264.7 cells by modulating
RANKL signaling. J. Lipid Res. 47, 1739–1748.
[17] Lee, Z.H. and Kim, H.H. (2003) Signal transduction by receptor activator of
nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305,
211–214.
[18] Raisz, L. (2005) Pathogenesis of osteoporosis: concepts, conﬂicts, and
prospects. J. Clin. Invest. 115, 3318–3325.
[19] Ishikawa, H. and Barber, G.N. (2008) STING is an endoplasmic reticulum
adaptor that facilitates innate immune signaling. Nature 455, 674–678.
[20] Boyle, W.J., Simonet, W.S. and Lacey, D.L. (2003) Osteoclast differentiation and
activation. Nature 423, 337–342.
[21] Tsubaki, M., Komai, M., Itoh, T., Imano, M., Sakamoto, K., Shimaoka, H., Takeda,
T., Ogawa, N., Mashimo, K., Fujiwara, D., Mukai, J., Sakaguchi, K., Satou, T. and
Nishida, S. (2014) Nitrogen-containing bisphosphonates inhibit RANKL- and
M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt
activation. J. Biomed. Sci. 21, 10.
[22] Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Lüthy, R.,
Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M.,
Elliott, R., Colombero, A., Tan, H.L., Trail, G., Sullivan, J., Davy, E., Bucay, N.,
Renshaw-Gegg, L., Hughes, T.M., Hill, D., Pattison, W., Campbell, P., Sander, S.,
Van, G., Tarpley, J., Derby, P., Lee, R. and Boyle, W.J. (1997) Osteoprotegerin: a
novel secreted protein involved in the regulation of bone density. Cell 89,
309–319.
[23] Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D.L. and
Dunstan, C.R. (1999) A chimeric form of osteoprotegerin inhibits
hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH,
PTHrP, and 1, 25(OH)2D3. J. Bone Miner. Res. 14, 1478–1485.
[24] Gallagher, J.C. and Sai, A.J. (2010) Molecular biology of bone remodeling:
implications for new therapeutic targets for osteoporosis. Maturitas 65, 301–
307.
[25] Cauley, J.A., Robbins, J., Chen, Z., Cummings, S.R., Jackson, R.D., LaCroix, A.Z.,
LeBoff, M., Lewis, C.E., McGowan, J., Neuner, J., Pettinger, M., Stefanick, M.L.,
Wactawski-Wende, J. and Watts, N.B. (2003) Effects of estrogen plus progestin
on risk of fracture and bone mineral density: the Women’s Health Initiative
randomized trial. JAMA 290, 1729–1738.
[26] Hadji, P. (2012) The evolution of selective estrogen receptor modulators in
osteoporosis therapy. Climacteric 15, 513–523.
[27] Papapetrou, P.D. (2009) Bisphosphonate-associated adverse events. Hormones
(Athens) 8, 96–110.
